Phenytoin Systematic (IUPAC) name 5,5-diphenylimidazolidine-2,4-dione Clinical data Trade names Dilantin AHFS/Drugs.com MedlinePlus Pregnancy cat. D Legal status ℞ Prescription only Routes Oral, parenteral Pharmacokinetic data Bioavailability 70-100% oral, 24.4% for rectal and intravenous administration Protein binding 90% Metabolism hepatic Half-life 6–24 hours Excretion Primarily through the bile, urinary Identifiers CAS number ATC code N03 N03, N03 PubChem DrugBank ChemSpider UNII KEGG ChEBI ChEMBL Chemical data Formula C15H12N2O2 Mol. mass 252.268 g/mol SMILES & (what is this?)
Phenytoin sodium is a commonly used antiepileptic. Phenytoin (fœnit'oin, IPA) acts to suppress the abnormal brain activity seen in seizure by reducing electrical conductance among brain cells by stabilizing the inactive state of voltage-gated sodium channels. Aside from seizures, it is an option in the treatment of trigeminal neuralgia in the event that carbamazepine or other first-line treatment seems inappropriate.
Phenytoin sodium has been marketed as Phenytek by Mylan Laboratories, previously Bertek Pharmaceuticals, and Dilantin; Australia also Dilantin Kapseals and Dilantin Infatabs in the USA, Eptoin by Abbott Group in India and as Epanutin in the UK and Israel, by Parke-Davis, now part of Pfizer. In the USSR and post-USSR countries, it was/is marketed as Дифенин (Diphenin, Dipheninum),.
Phenytoin (diphenylhydantoin) was first synthesized by German chemist Heinrich Biltz in 1908. Biltz sold his discovery to Parke-Davis, which did not find an immediate use for it. In 1938, outside scientists including H. Houston Merritt and Tracy Putnam discovered phenytoin's usefulness for controlling seizures, without the sedative effects associated with phenobarbital.
According to Goodman and Gilman's Pharmacological Basis of Therapeutics,
- In contrast to the earlier accidental discovery of the antiseizure properties of bromide and phenobarbital, phenytoin was the product of a search among nonsedative structural relatives of phenobarbital for agents capable of suppressing electroshock convulsions in laboratory animals.
There are some indications that phenytoin has other effects, including anxiety control and mood stabilization, although it has never been approved for those purposes by the FDA. Jack Dreyfus, founder of the Dreyfus Fund, became a major proponent of phenytoin as a means to control nervousness and depression when he received a prescription for Dilantin in 1966. He is believed to have supplied large amounts of the drug to Richard Nixon throughout the late 1960s and early 1970s. Dreyfus' experience with phenytoin is outlined in his book, A Remarkable Medicine Has Been Overlooked,. Despite more than $70 million in personal financing, his push to see phenytoin evaluated for alternative uses has had little lasting effect on the medical community. This was partially because Parke-Davis was reluctant to invest in a drug nearing the end of its patent life, and partially due to mixed results from various studies. It was approved by the USA Food and Drug Administration in 1953 for use in seizures.
In 2008, the drug was put on the FDA's Potential Signals of Serious Risks List to be further evaluated for approval. The list means that the FDA has identified a potential safety issue, but does not mean that FDA has identified a causal relationship between the drug and the listed risk.
According to the FDA's New Safety Information Identified by the Adverse Event Reporting System (AERS) Phenytoin Injection (Dilantin) has been associated with the risk of Purple Glove Syndrome.
At therapeutic doses, phenytoin produces horizontal gaze nystagmus. At toxic doses, patients experience sedation, cerebellar ataxia, and ophthalmoparesis, as well as seizures. Idiosyncratic side-effects of phenytoin, as with other anticonvulsants, include rash and severe allergic reactions.
Phenytoin may accumulate in the cerebral cortex over long periods of time, as well as causing atrophy of the cerebellum when administered at chronically high levels. Despite this, the drug has a long history of safe use, making it one of the more popular anti-convulsants prescribed by doctors, and a common "first line of defense" in seizure cases.
It has been suggested that phenytoin causes a reduction in folic acid levels, predisposing patients to megaloblastic anemia. Folic acid is presented in foods as polyglutamate, which is then converted into monoglutamates by intestinal conjugase. Phenytoin acts by inhibiting this enzyme, thereby causing folate deficiency. Other side effects may include: agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia.
Phenytoin is a known teratogen. The syndrome consists of craniofacial anomalies (broad nasal bridge, cleft lip and palate, microcephaly) and a mild form of mental retardation (average IQ=71). This syndrome resembles the well-described Fetal Alcohol Syndrome and has also been called the "fetal hydantoin syndrome". Data now being collected by the Epilepsy and Antiepileptic Drug Pregnancy Registry may one day answer this question definitively.
Some recommend avoiding polytherapy and maintaining the minimal dose possible during pregnancy, but acknowledge that current data do not provide clear answers.
Phenytoin has been associated with drug-induced gingival enlargement (overgrowth of the gums), probably due to above-mentioned folate deficiency; indeed, evidence from a randomized controlled trial suggests that folic acid supplementation can prevent gingival enlargement in children who take phenytoin. Plasma concentrations needed to induce gingival lesions has not been clearly defined. Effects consist of the following: bleeding upon probing, increased gingival exudate, pronounced gingival inflammatory response to plaque levels, associated in some instances with bone loss but without tooth detachment.
Following almost 200 studies of 11 anti-seizure drugs, the FDA has also warned of an increased suicide risk for any patients treated with certain anti-seizure drugs. The study of 44,000 patients found that patients whose epilepsy is treated with drugs face about twice the risk of suicidal thoughts compared to placebo-takers. Although phenytoin was not named in the study, the FDA announced that it expected the risk applied to every epilepsy drug.
Hypertrichosis, rash, exfoliative dermatitis, pruritis.
In autoimmune disease
Phenytoin therapy has been linked to the life-threatening skin reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These conditions are significantly more common in patients with a particular HLA-B allele, HLA-B*1502. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians.
In immunodeficiency disease
Phenytoin is also associated with induction of reversible IgA deficiency.
Warfarin (Coumadin) increases serum phenytoin levels and prolongs the serum half-life of phenytoin by inhibiting its metabolism.
Phenytoin kinetics are nonlinear and saturable, resulting in highly variable concentrations even with minor dosage changes. A small increase in dose may lead to a large increase in drug concentration as elimination becomes saturated.
Phenytoin, 5,5-diphenylimidazolidinedione is synthesized in two different ways. The first involves a base catalyzed addition of Urea to benzil followed by a benzilic acid rearrangement (1,2 phenyl migration) to form the desired product. This is known as the Biltz Synthesis of phenytoin.
The second method involves the reaction of benzophenone with sodium cyanide in the presence of ammonium carbonate, followed by the simultaneous cyclization of the resulting product (carboxyaminonitrile) and its rearrangement under the reaction conditions to form phenytoin.
- US patent 2409754, Hense, H. R., "Method for obtaining hydantoins", issued 1946-10-22, assigned to Parke Davis
- ^ Balaji S (October 2004). "Medical therapy for sudden death". Pediatr. Clin. North Am. 51 (5): 1379–87. doi:10.1016/j.pcl.2004.04.002. PMID 15331289. http://linkinghub.elsevier.com/retrieve/pii/S0031395504000513.
- ^ a b Biltz, H. (1908). "Constitution of the Products of the Interaction of Substituted Carbamides on Benzil and Certain New Methods for the Preparation of 5,5-Diphenylhydantoin". Chemische Berichte 41: 1379–93.
- ^ Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th ed. (New York: McGraw-Hill, 2001).
- ^ Dreyfus, Jack (1998). A Remarkable Medicine Has Been Overlooked: Including an Autobiography and the Clinical Section of the Broad Range of Use of Phenytoin. Continuum International Publishing Group. ISBN 0-8264-1069-3.
- ^ Carl GF, Smith ML (1992). "Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin". Epilepsia 33 (2): 372–5. doi:10.1111/j.1528-1157.1992.tb02330.x. PMID 1547769.
- ^ Beckmann, Charles R., et al. (2002). Obstetrics and Gynecology (4th ed.). Baltimore: Lippincott Williams & Wilkins.
- ^ CDC. (2004). Fetal Alcohol Syndrome: Guidelines for Referral and Diagnosis. Can be downloaded at http://www.cdc.gov/fas/faspub.htm.
- ^ Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J (2004). Adab, Naghme. ed. "Common antiepileptic drugs in pregnancy in women with epilepsy". Cochrane Database Syst Rev (3): CD004848. doi:10.1002/14651858.CD004848. PMID 15266543.
- ^ Report on Carcinogens, Eleventh Edition (PB2005-104914, 2004) p III-216.
- ^ Maeda T, Sano N, Togei K, Shibata M, Izumi K, Otsuka H (1988). "Lack of carcinogenicity of phenytoin in (C57BL/6 x C3H)F1 mice". J Toxicol Environ Health 24 (1): 111–9. doi:10.1080/15287398809531144. PMID 3373561.
- ^ Arya R, Gulati S, Kabra M, Sahu JK, Kalra V (Apr 2011). "Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children". Neurology 76 (15): 1338–43. doi:10.1212/WNL.0b013e3182152844. PMC 3090066. PMID 21482950. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3090066.
- ^ FDA warns of risks from epilepsy drugs.. http://news.yahoo.com/s/ap/20080201/ap_on_he_me/epilepsy_drugs
- ^ Scheinfeld N (August 2003). "Phenytoin in cutaneous medicine: its uses, mechanisms and side effects". Dermatol. Online J. 9 (3): 6. PMID 12952753. http://dermatology.cdlib.org/93/reviews/dilantin/scheinfeld.html.
- ^ a b Man CB, Kwan P, Baum L, et al. (May 2007). "Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese". Epilepsia 48 (5): 1015–8. doi:10.1111/j.1528-1167.2007.01022.x. PMID 17509004.
- Medicines for Epilepsy: Dilantin Epilepsy Foundation (broken link).
- Remarkable Medicine, a website about the Dreyfus Foundation's work to expand the indications for phenytoin
- Phenytoin Pharmacokinetics (not a public link)
Anticonvulsants (N03) GABAA receptor agonist Other GABA agents Carbonic anhydrase inhibitor Channel blockersPrimarily sodiumPrimarily calciumUnknown/ungrouped Channel openersPotassiumRetigabine Indirect GABA agents Unknown/multiple/
Antiarrhythmic agents (C01B) Channel blockersclass Ib (Phase 3←)class Ic (Phase 0→) Receptor agonists
Wikimedia Foundation. 2010.
Look at other dictionaries:
Phenytoin — Strukturformel Allgemeines Freiname Phenytoin Andere Namen … Deutsch Wikipedia
Phenytoin — Phe|ny|to|in [Kurzw. aus 5,5 Diphenylhydantoin], das; s: Freiname für ein Antiepileptikum u. Antiarrhythmikum. * * * Phenytoin das, s, ein Derivat des Hydantoins … Universal-Lexikon
phenytoin — noun Etymology: diphenylhydantoin Date: 1941 a crystalline anticonvulsant compound C15H12N2O2 used in the form of its sodium salt in the treatment of epilepsy called also diphenylhydantoin … New Collegiate Dictionary
phenytoin — /fen i toh in, feuh nit oh /, n. Pharm. a barbiturate related substance, C15H12N2O2, used as an anticonvulsant in the treatment of grand mal epilepsy and in focal seizures. [1940 45; (di)pheny(lhydan)toin, its full chemical name; see DI 1, PHENYL … Universalium
phenytoin — noun An anticonvulsant drug, 5,5 diphenylimidazolidine 2,4 dione, used in the treatment of epilepsy … Wiktionary
phenytoin — An anticonvulsant used in the treatment of generalized tonic clonic and complex partial epilepsy. Also available as p. sodium, with the same uses as p.. SYN: 5,5 diphenylhydantoin. * * * phe·nyt·o·in fə nit ə wən n an anticonvulsant used in the… … Medical dictionary
phenytoin — [fɛ nɪtəʊɪn] noun Medicine a synthetic compound used as an anticonvulsant in the treatment of epilepsy. Origin 1940s: blend of phenyl and hydantoin … English new terms dictionary
phenytoin — phe·nyt·o·in … English syllables
phenytoin — n. an anticonvulsant drug used to control major and focal epileptic seizures and status epilepticus. It is administered by mouth or intravenous injection; side effects include nausea and vomiting, confusion, dizziness, headache, tremor, insomnia … The new mediacal dictionary
phenytoin — phen•y•to•in [[t]ˌfɛn ɪˈtoʊ ɪn, fəˈnɪt oʊ [/t]] n. pha a barbiturate related substance, C15H12N2O2, used as an anticonvulsant in the treatment of epilepsy • Etymology: 1940–45; shortening of diphenylhydantoin= di I+phenyl+hydantoin a crystalline… … From formal English to slang